with chemoradiation, Food and Drug Administration (FDA)-approved treatments such as intracavitary chemotherapy wafers, bevacizumab, and alternating electrical fields [1] with median survival times of approximately 15 months from diagnosis. [2] Numerous promising therapeutic modalities (targeted kinase inhibitors, anti-angiogenic treatments, immunotherapies) have been tested in advanced clinical trials without lasting success.There has been a resurgence of interest in therapeutic modalities that stimulate the immune system against tumor cells. However, immune checkpoint inhibitors (ICI) have generally not been as successful against GBM as they have been for other cancers. [3] Although there is still interest in ICI therapy alone in a neo-adjuvant setting, [4] the neuro-oncology community has been trying to explain its limited efficacy. One accepted explanation is that the GBM microenvironment is dominated by profound myeloid immunosuppression and continuous changes and adaptation to therapies. [5][6][7] This immunosuppression inhibits effective immune surveillance by altering the ability of anti-tumor effector immune cells (T cells, macrophages (MF), natural killer (NK) cells) to infiltrate and destroy the GBM.Myeloid cells are abundant, create a highly immunosuppressive environment in glioblastoma (GBM), and thus contribute to poor immunotherapy responses. Based on the hypothesis that small molecules can be used to stimulate myeloid cells to elicit anti-tumor effector functions, a synthetic nanoparticle approach is developed to deliver dual NF-kB pathway-inducing agents into these cells via systemic administration. Synthetic, cyclodextrinadjuvant nanoconstructs (CANDI) with high affinity for tumor-associated myeloid cells are dually loaded with a TLR7 and 8 (Toll-like receptor, 7 and 8) agonist (R848) and a cIAP (cellular inhibitor of apoptosis protein) inhibitor (LCL-161) to dually activate these myeloid cells. Here CANDI is shown to: i) readily enter the GBM tumor microenvironment (TME) and accumulate at high concentrations, ii) is taken up by tumor-associated myeloid cells, iii) potently synergize payloads compared to monotherapy, iv) activate myeloid cells, v) fosters a "hot" TME with high levels of T effector cells, and vi) controls the growth of murine GBM as mono-and combination therapies with anti-PD1. Multi-pathway targeted myeloid stimulation via the CANDI platform can efficiently drive anti-tumor immunity in GBM.